Tandem Diabetes (TNDM) Tops Q4 EPS by 7c, Beats on Revenues; Offers FY18 Revenue Outlook Above Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Tandem Diabetes Care (TNDM) PT Raised to $4 at Stifel
March 5, 2018 7:16 AM ESTStifel raised its price target on Tandem Diabetes Care (NASDAQ: TNDM) to $4.00 (from $3.00) while maintaining a Hold rating following the company's 4Q. sales were at the high end of the companys January 9th pre-announced $39-$40M range, and the company exited 2017 with record... More
Tandem Diabetes Care (TNDM) PT Doubled to $5 at Cowen; Outlook Improved Significantly
February 27, 2018 9:39 AM ESTCowen raised its price target on Tandem Diabetes Care (NASDAQ: TNDM) to $5.00 (from $2.50) while maintaining a Market Perform rating.
Analyst Doug Schenkel commented, "The outlook has significantly improved. For the first time since we began covering TNDM, we believe there is a... More
Oppenheimer Starts Tandem (TNDM) at Outperform
February 27, 2018 8:14 AM ESTOppenheimer initiates coverage on Tandem (NASDAQ: TNDM) with a Outperform rating and a price target of $5.50.
For an analyst ratings summary and ratings history on Tandem click here. For more ratings news on Tandem click here.
Shares of Tandem closed at $3.10 yesterday.
... More